Purpose: to assess the safety and efficacy of infliximab in the treatment of uveitis associated with Behcet's disease. Methods: fifty patients with Behcet's related uveitis were included in this prospective comparative study. Cases were divided into 2 groups; group A(25 patients) received infliximab and group B (25 patients) received oral steroids. All cases were followed up to one year. Results: In group A, the mean BCVA (logMAR) improved from  0.48±0.14 at baseline  to 0.07±0.12 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 18 after 3 months.  In group B, the mean BCVA (logMAR) improved from  0.47±0.13 at baseline  to  0.17±0.15 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 14 after 3 months. Conclusion: Infliximab is both safe and effective in treating uveitis associated with Behcet's disease. Studies with larger sample size and longer follow-up periods are needed to confirm the results.